Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey.

Abstract

OBJECTIVES\nThe CONVERT trial showed that twice-daily (BD) concurrent chemoradiotherapy should continue to be considered the standard of care in localised LS-SCLC. A survey was conducted to assess the impact of the CONVERT trial in clinical practice and to identify any relevant research questions for future trials in this setting.\n\n\nMETHODS AND MATERIALS\nAn EORTC Group online survey of LS-SCLC practice was distributed to the EORTC LCG and to members of several European thoracic oncology societies between April and December 2018.\n\n\nRESULTS\n198 responses were analysed. The majority of respondents (88%, n\u202f=\u202f174) were aware of the CONVERT trial. Radiation oncologists comprised 56% of all respondents. Once-daily (OD) radiotherapy is still the most commonly used regimen, however the use of concurrent BD radiotherapy increased after the publication of CONVERT (n\u202f=\u202f59/186, 32% prior to and n\u202f=\u202f78/187, 42% after the publication, p\u202f=\u202f0.053). The main reasons for not implementing BD after the CONVERT publication were logistical issues (n\u202f=\u202f88, 44%), inconvenience for patients (n\u202f=\u202f56, 28%), and the absence of a statistical survival difference between the two arms in CONVERT (n\u202f=\u202f38, 19%). Brain MRI was used by 28% during staging but more than half (60%) of the respondents did not routinely image the brain during follow-up. The main research questions of interest in LS-SCLC were 1) integrating novel targeted therapies-immunotherapies (n\u202f=\u202f160, 81%), 2) PCI (+/- hippocampal sparing) vs. MRI surveillance (n\u202f=\u202f140, 71%) and, 3) biomarker driven trials (n\u202f=\u202f92, 46%).\n\n\nCONCLUSION\nOnce daily radiotherapy (60-66\u202fGy in 30-33 fractions) remains the most prescribed radiotherapy fractionation, despite the findings suggested by the CONVERT trial.